The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC
Natasha Leighl, MD, FASCO, Princess Margaret Cancer Centre, Toronto, Canada, discusses the findings of the Phase III PALOMA-3 (NCT05388669) trial, which evaluated subcutaneous (SC) versus intravenous (IV) administration of amivantamab plus lazertinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The study met its co-primary endpoints, demonstrating noninferior pharmacokinetics (PK) and objective response rate (ORR) for SC administration. SC amivantamab showed a median progression-free survival (PFS) of 6.1 months versus 4.3 months for IV, and an overall survival (OS) advantage with a hazard ratio of 0.62. The SC form also resulted in significantly lower infusion-related reactions (IRRs) and venous thromboembolism (VTE) rates. These results suggest a favorable profile for SC administration in terms of efficacy and safety. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Beigene; BMS; Janssen; MSD Oncology; Takeda
Research Funding – AstraZeneca Canada (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses – AstraZeneca
